Journals / Retina-Vitreus / 2017 / Cilt: 26 - Sayı: 0

Actual Treatment for ROP

ROP’ta Güncel Tedavi

Pages
38–43
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

All eff ors should be investigated in develo- ping new therapy modalities including management algorith in current ROP treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Retinopathy of prematurity (ROP) is the major cause of visuel impairment and blindness in prematu re neonates.
📊
Key Findings & Data:Intravitreal anti-VEGF therapy has been proven to be more eff ective in terms of lowering recurrence, rates al- lowing growth of the peripheral retina, and diminishing the incidence of retinal detachment when proliferative ROP was diagnosed, more particularly in Zon-I- ROP and AP-ROP.
💡
Conclusion & Impact:All eff ors should be investigated in develo- ping new therapy modalities including management algorith in current ROP treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Retinopathy of prematurity (ROP) is the major cause of visuel impairment and blindness in prematu re neonates. ROP is a complex multifactorial diesease with microvascular dejene- ration at diff erent stages followed by neovascularisation and some cases resulting in retinal detachment. Current standart ablative therapy, like laser photocaogulation for proliferative ROP have limitations and patients can stil have long-term complications despite successful treatment. Based on know- ledge on ROP patophysiology new treatment modalities are developing. Intravitreal anti-VEGF therapy has been proven to be more eff ective in terms of lowering recurrence, rates al- lowing growth of the peripheral retina, and diminishing the incidence of retinal detachment when proliferative ROP was diagnosed, more particularly in Zon-I- ROP and AP-ROP. Whether anti-VEGF plus laser are better options than any of these therapies separately remains a subject of discussion. First results of intravitreal anti-VEGF therapy using anti-VE- GF are promising. The importance of fl uorescein angiography in long term-follow up after intravitreal anti-VEGF injection has be clarified. All eff ors should be investigated in develo- ping new therapy modalities including management algorith in current ROP treatment.

Özet

Prematüre retinopatisi (Prematüre retinopatisi= retinopathy of pramturity = ROP) prematüre bebeklerde görülen, geliş- mekte olan retina vasküler yapılanmasında patolojik gelişim ile seyreden ve prematüre doğmuş bebeklerde görme kaybına neden olan vasküler hastalıktır. Günümüzde ROP tedavisin- de altın standart olan lazer fotokoagülasyon tedavisi sınırlı etkili kalabilmektdir ve uzun vadede başarılı tedaviye rağmen geç komplikasyonlar gelişebilmektedir. Prematüre retinopati- sinin evresine uygun patofizyolojisinden yola çıkarak daha az destrüktif ve bugüne kadar kullanılan tedavi yöntemlerinden daha güvenilir tedavi yöntemleri aranmakta ve geliştirilmek- tedir. Anti-VEGF (vasküler endotelyal büyüme faktörü) teda- visi umut vaad edicidir. İntravitreal anti-VEGF tedavisinin özellikle agresif posterior-ROP (AP-ROP) ve Zon-I olgularında nüks riskini azaltarak, perifer retinal vasküler yapılanmaya olanak sağlayarak daha efektif tedavi seçeneği olduğu düşü- nülmektedir. Anti-VEGF tedavisi veya anti-VEGF ile laser te- davisinin kombinasyonun tedavi şemasında birbirine üstün- lüğü ve özellikle anti-VEGF sonrası uzun dönem takiplerde fundus fl uoresein anjiografinin yeri henüz kesinleşmemiştir ve prospektif randomize çalışmalarda ROP için güncelleşti- rilmiş tedavi ve takip protokolü algoritması geliştirilmelidir.

🔖

Cite This Article

AKKOYUN, İ. (2017). Actual Treatment for ROP. Retina-Vitreus, Cilt: 26 - Sayı: 0, 38–43. https://ajindex.com/articles/304925

References (7)

  1. Kong L, Fry M, Samarriae MA et al. An update on progress and the changing epidemiology of causes of childhood blindness wor- ldwide. J AAPOS 2012;16:501–507 Fierson WM; American Academy of Pediatrics Section on Opht- halmology; American Academy of Ophthalmology; American As- sociation for Pediatric Ophthalmology and Strabismus; Ameri- can Association of Certifi ed Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013;131:189–195. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005; 123: 991-999 [PMID: J pediatr 2016;168:242-244, J pediatr 2016;168:242-244.
  2. ETROP, Early Treatment For Retinopathy Of Prematurity Co- operative Group. Revised indications for the treatment of reti- nopathy of prematurity: results of the early treatment for re- tinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684-94.
  3. Hellström A, Ley D, Hansen-Pupp I, et al. New insights into the development of retinopathy of prematurity - importance of early weight gain. Acta Paediatr 2010;99:502-08.
  4. Cernichiaro-Espinosa LA, Olguin-Manriquez FJ, Henaine-Berra A et al. New insights in diagnosis and treatment for Retinopathy of Prematurity. Int Ophthalmol. 2016;36:751-60.
  5. Pandya HK, Faia LJ, Robinson J et al. Macular Development in Aggressive Posterior Retinopathy of Prematurity. Biomed Res Int. 2015;2015:808639. doi: 10.1155/2015/808639. Epub 2015 Jun 18. Sanghi G, Dogra MR, Katoch D et al. Aggressive posterior reti- nopathy of prematurity in infants ≥ 1500 g birth weight. Indian J Ophthalmol. 2014 Feb;62:254-7.
  6. Drenser KA, Trese MT, Capone A Jr. et al. Aggressive posterior retinopathy of prematurity. Retina. 2010;30:37-40. Eff icacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BE- AT-ROP Cooperative Group). N Engl J Med. 2011;364:603-15. Screening examination of premature infants for retinopathy of prematurity. Fierson WM; American Academy of Pediatrics Se- ction on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabis- mus; American Association of Certified Orthoptists. Pediatrics. 2013;131:189-95.
  7. Hwang CK, Hubbard GB, Hutchinson AKet al. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Re- tinopathy of Prematurity: A 5-Year Retrospective Analysis. Oph- thalmol